Engineered immune cells take on tough leukemia
NCT ID NCT04010877
First seen May 03, 2026 · Last updated Jun 23, 2026 · Updated 12 times
Summary
This early-phase trial tests a combination of CAR T cells designed to attack three different targets on leukemia cells in patients with relapsed or refractory acute myeloid leukemia. Ten participants will receive infusions of these engineered immune cells to see if the treatment is safe and can shrink or eliminate the cancer. The study also aims to understand how long the CAR T cells last in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CAR T cells targeting CLL-1, CD33, and/or CD123
What this could lead to
If successful, this could point toward a new treatment option for patients with hard-to-treat acute myeloid leukemia.
What could go wrong
This is a very early, small trial with only 10 participants, so results may not apply broadly. CAR T therapy can cause severe side effects like cytokine release syndrome.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.